Trinds, LLC

Trinds, LLC delivers specialized contract research organization (CRO) services focused on clinical trials for neuromuscular and rare diseases, emphasizing effective trial management and data monitoring. Trinds, LLC is a contract research organization that supports clinical trials specifically related to neuromuscular disorders. Founded in 2016, the company is based in Pittsburgh, US. The founders include Eric Hoffman and Heather Gordish-Dressman, and the company is currently led by CEO Lauren Morgenroth.

In December 2016, Trinds, LLC raised venture financing from CureDuchenne Ventures. Trinds specializes in comprehensive contract research organization (CRO) services that cater to the clinical trial needs of neuromuscular and rare diseases. Their core offerings include trial management, clinical monitoring, site management, data management, and the development of tailored study outcome measures. With expertise from the Cooperative International Neuromuscular Research Group (CINRG), Trinds focuses on muscular dystrophies, particularly Duchenne muscular dystrophy (DMD).

Their clients include pharmaceutical and biotechnology companies, academic institutions, and healthcare organizations, with services deployed across North America, Europe, and parts of Asia. Trinds generates revenue through a B2B service model by engaging pharmaceutical and biotechnology companies for specialized CRO services. Revenue streams include fees for trial management, data monitoring services, and domain-specific solutions like genetic counseling, with pricing structures based on project scope and complexity, mutually agreed upon with clients prior to project initiation. Trinds plans to leverage funding raised in December 2016 to support the development of new products and expand into additional markets.

The strategic focus includes enhancing their service offerings tailored to the evolving challenges in neuromuscular clinical trials. The company aims to explore opportunities in regions beyond its current markets and intends to implement these initiatives by the end of 2018.